Evaluation of SARC-F and SARC-CalF for sarcopenia screening in patients with chronic musculoskeletal pain
A prospective cross-sectional study

Hironori Tsuji, MD, PhD\(^a\), Tomoko Tetsunaga, MD, PhD\(^{b,c,*}\), Tomonori Tetsunaga, MD, PhD\(^b\), Haruo Misawa, MD, PhD\(^b\), Yoshiaki Oda, MD, PhD\(^b\), Shinichiro Takao, MD\(^c\), Keiichiro Nishida, MD, PhD\(^{b,c}\), Toshifumi Ozaki, MD, PhD\(^d\)

Abstract

Objectives: Early sarcopenia detection using screening tools, such as SARC-F and SARC-CalF, has been proven reliable. However, the relationship between chronic musculoskeletal pain with sarcopenia is unknown. This study assessed sarcopenia morbidity as well as the reliability of sarcopenia screening with SARC-F and SARC-CalF in patients with chronic musculoskeletal pain.

Methods: Overall, 172 patients with chronic musculoskeletal pain were included in this cross-sectional study. All participants completed the SARC-F, SARC-CalF, numeric rating scale (NRS), and pain disability assessment scale (PDAS) assessments. Sarcopenia was diagnosed using the Asian Working Group for Sarcopenia criteria 2019. Correlations between SARC-F and SARC-CalF scores and each measured variable were evaluated using univariate and multiple linear regression analyses. A receiver operating characteristic curve analysis was conducted, and reliabilities of SARC-F and SARC-CalF scores for diagnosing sarcopenia were compared.

Results: Thirty-nine patients were diagnosed with sarcopenia. Among these, 10 patients were <65 years old, and 29 were >65 years old. Both SARC-F and SARC-CalF scores significantly correlated with grip power, gait speed, skeletal mass index, numeric rating scale score, and PDAS score. In multiple linear regression analysis, SALC-F and SARC-CalF scores significantly correlated with PDAS score, skeletal mass index, and gait speed. The area under the curve were 0.70 for SARC-F and 0.88 for SARC-CalF; SARC-CalF had a significantly higher area under the curve than SARC-F.

Discussion: Sarcopenia was diagnosed in patients aged <65 years with chronic musculoskeletal pain. SALC-F and SARC-CalF scores showed a significant correlation with disability due to pain and were reliable sarcopenia screening tools for chronic musculoskeletal pain. SARC-CalF was more reliable than SARC-F.

Abbreviations: ADL = activities of daily living, AUC = area under the curve, AWGS = Asian Working Group for Sarcopenia, CC = calf circumference, LR = likelihood ratio, NPV = negative predictive value, NRS = Numeric Rating Scale, PDAS = pain disability assessment scale, PPV = positive predictive value, ROC = receiver operating characteristic, SMI = skeletal muscle index.

Keywords: chronic musculoskeletal pain, SARC-CalF, SARC-F, Sarcopenia, screening

1. Introduction

As the population of older adults in developed countries rises, so does the number of people requiring nursing care services, with approximately 21.5% of these people requiring nursing care for musculoskeletal disorders.\(^{11}\) Thus, early detection, prevention, and treatment of musculoskeletal disorders are important objectives for reducing the number of older people who require nursing care and extending healthy life expectancy. From this perspective, sarcopenia is a rising concern.\(^{[2–8]}\) Sarcopenia is defined as a progressive and generalized skeletal muscle disorder that involves accelerated loss of muscle mass and function.\(^{[9,10]}\) It is associated with increased adverse outcomes, including functional decline, falls, fractures, and even mortality.\(^{[5,11–13]}\) Although sarcopenia is...
common among older adults, it can also occur earlier in life, making early detection essential for the prevention and treatment of this condition.[5] Among the existing screening tools, SARC-F and SARC-CalF are commonly recommended instruments, with the evidence available to support their use.[14,15]

Chronic pain is another problem that decreases activities of daily living (ADL), affecting 20% of the general population.[16,17] The International Association for the Study of Pain and the World Health Organization have included chronic musculoskeletal pain in the International Statistical Classification of Diseases-11.[18,19] Chronic musculoskeletal pain causes decreased physical function due to prolonged pain, whose onset can be in patients as young as 40 years of age.[20] While both chronic pain and sarcopenia decrease physical function and activity, the relationship between them is not well-defined. Moreover, from the perspective of prevention, screening for sarcopenia in patients with chronic musculoskeletal pain is important. Therefore, this study aimed to assess the morbidity of sarcopenia and evaluate the reliability of screening sarcopenia using SARC-F and SARC-CalF in patients with chronic musculoskeletal pain.

2. Methods

2.1. Study participants

This cross-sectional study was conducted at Okayama University Hospital. We included 172 patients (43 men, 129 women) with chronic musculoskeletal pain who presented to our outpatient pain clinic between December 2019 and February 2021. The inclusion criteria for this study were age over 40 years, pain for >3 months, and consent to complete written self-report questionnaires and a physical examination. The exclusion criteria were as follows: ongoing litigation, dementia, delirium, or other conditions that would make completion of questionnaires and physical examinations difficult. Participants were requested to complete questionnaires and undergo a physical examination and body composition assessment at the outpatient clinic. Ethical approval was obtained from the Board of Ethics of Okayama University Hospital. This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

2.2. Assessment of sarcopenia-related factors

2.2.1. Diagnosis of Sarcopenia. Diagnosis of sarcopenia was performed according to the Asian Working Group for Sarcopenia (AWGS) criteria 2019.[6] Gait speed, grip strength, and muscle mass were assessed and used in this study. The criterion for low muscle strength was handgrip strength <28 kg for men and <18 kg for women and the criterion for low physical performance was 6-m walking speed <1.0 m/s. The skeletal muscle index (SMI) was assessed using Inbody 770 and S10 (InBody Japan, Tokyo, Japan), and low muscle mass was defined by an SMI <7.0 kg/m² in men and <5.7 kg/m² in women in this study. Sarcopenia was defined by the presence of low muscle mass and either low muscle strength or low physical performance.

2.2.2. SARC-F and SARC-CalF as Screening Tools for Sarcopenia. SARC-F and SARC-CalF were used to screen for sarcopenia in this study.[21–24] The SARC-F comprises five items, assessing participant strength, assistance in walking, rising from a chair, climbing stairs, and falls. Each item is scored between 0 and 2.[21] SARC-CalF comprises the items from SARC-F and one additional calf circumference (CC) item. The first five items are scored the same as in the standard SARC-F. The CC item is scored if the CC is >34 cm for men and >33 cm for women and 10 points if the CC is ≤34 cm for men and ≤33 cm for women.[15] A total SARC-F score ≥4 and SARC-CalF score ≥11 indicate a positive result for sarcopenia.

The pain disability assessment scale (PDAS) was used to assess the extent to which pain interfered with patients’ ADL during the previous week.[25] The PDAS comprises 20 items; each item is rated from 0 to 3, with 0 representing “pain did not interfere with this activity” and 3 representing “pain interfered with this activity.” The PDAS scores range from 0 to 60, and a higher score indicates a greater pain-related interference.

2.4. Statistical analyses

Descriptive statistics are presented as mean ± standard deviations (SDs) for continuous variables and as numbers and percentages for categorical variables. The Kolmogorov–Smirnov test was used to assess normality for continuous variables. Next, we performed the Mann–Whitney U test to compare the measured parameters in patients with and without sarcopenia. We subsequently analyzed correlations of SARC-F and SARC-CalF scores with each measured variable using Spearman’s rank correlation coefficient. We then performed multiple linear regression to determine the factors associated with SARC-F and SARC-CalF scores. The explanatory variables included grip power, gait speed, SMI, and NRS and PDAS scores, while the covariates were age, sex (male = 1 and female = 0), and BMI. The standardized partial regression coefficient of each variable was calculated. Next, to evaluate the diagnostic value of SARC-F and SARC-CalF scores, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR−) were evaluated. Subsequently, a receiver operating characteristic curve (ROC) analysis was performed, and the results were compared between SARC-F and SARC-CalF.

For the statistical analyses, we used EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan). The results were compared between SARC-F and SARC-CalF.

### Table 1: Patient characteristics.

| Variables                        | All (n = 172) | <65 years (n = 75) | ≥65 years (n = 97) |
|----------------------------------|--------------|-----------------|-----------------|
| Patient background               |              |                 |                 |
| Age (years)                      | 66.6 ± 13.9  | 52.9 ± 6.8      | 77.2 ± 6.9      |
| Sex (men/women)                  | 43/129       | 20/55           | 23/74           |
| BMI (kg/m²)                      | 23.8 ± 4.5   | 24.0 ± 5.4      | 23.6 ± 3.7      |
| Sarcopenia-related factor        |              |                 |                 |
| Sarcopenia                       | 36 (20.9)    | 7 (9.3)         | 29 (29.9)       |
| SARC-F (points)                  | 2.7 ± 2.5    | 1.6 ± 2.0       | 3.5 ± 2.5       |
| SARC-CalF (points)               | 7.0 ± 5.8    | 4.6 ± 4.9       | 9.0 ± 5.7       |
| Grip power (kg)                  | 20.2 ± 10.5  | 23.8 ± 10.9     | 17.5 ± 9.4      |
| Gait speed (m/s)                 | 1.1 ± 0.4    | 1.3 ± 0.4       | 1.0 ± 0.4       |
| SMI (kg/m²)                      | 6.7 ± 1.3    | 7.1 ± 1.3       | 6.3 ± 1.1       |
| Pain-related factor              |              |                 |                 |
| NRS (points)                     | 5.0 ± 2.5    | 4.9 ± 2.5       | 5.1 ± 2.4       |
| PDAS (points)                    | 17.0 ± 14.4  | 13.5 ± 12.0     | 19.4 ± 15.6     |
| Pain site                        |              |                 |                 |
| Cranio-cervical                  | 26 (15.0)    | 14 (18.7)       | 12 (12.4)       |
| Upper limb                       | 34 (19.8)    | 15 (20.0)       | 19 (19.6)       |
| Trunk                            | 96 (55.8)    | 41 (56.7)       | 55 (56.7)       |
| Lower limb                       | 84 (48.8)    | 30 (40.0)       | 54 (55.7)       |

Data are expressed as mean ± standard deviation for continuous variables and as number (%) for categorical variables.

BMI = body mass index, NRS = numeric rating scale, PDAS = pain disability assessment scale, SMI = skeletal muscle index.
### 3. Results

#### 3.1. Participant characteristics

The mean age was 66.6 years (SD: 13.9 years), mean SARC-F score was 2.7 (SD: 2.5), and mean SARC-CalF score was 7.0 (SD: 5.8). Among all patients, 75 patients were aged <65 years and 97 were aged >65 years; 36 (20.9%), 7 (9.3%), and 29 (29.9%) patients, respectively, were diagnosed with sarcopenia. Data for the other sarcopenia-related factors (grip power, gait speed, and SMI) and pain-related factors (NRS score, PDAS score, and pain site) are also shown in Table 1, and Table 2 shows the characteristics of patients with and without sarcopenia. For Statistical Computing, Vienna, Austria). Results were considered significant at a level of $P < .05$. To determine the number of test samples for multiple linear regression analysis, a prior sample size calculation was performed with effect size of 0.15, $\alpha$ error of 0.05, and (1-$\beta$) of 0.95 using G*power software version 3.1.9.7. This resulted in a required sample size of 160.

#### 3.2. Variables associated with SARC-F and SARC-CalF scores

Table 3 shows the results for the correlation between SARC-F and SARC-CalF scores and each variable. Both SARC-F and SARC-CalF scores were significantly correlated with grip power ($r = -0.501$ and -0.454), gait speed ($r = -0.675$ and -0.467), SMI ($r = -0.312$ and -0.557), NRS score ($r = 0.319$ and 0.255), and PDAS score ($r = 0.681$ and 0.441), and all $P$ values were <.001. In multiple linear regression analysis, SARC-F score was significantly correlated with PDAS score ($\beta = 0.49, P < .001$), SMI ($\beta = -0.28, P = .006$), and gait speed ($\beta = -0.29, P < .001$) (Table 4); SARC-CalF score was also significantly correlated with PDAS score ($\beta = 0.28, P < .001$), SMI ($\beta = -0.25, P = 0.038$), and gait speed ($\beta = -0.19, P = 0.020$) (Table 5).

#### 3.3. Diagnostic power and comparison of SARC-F and SARC-CalF scores

The diagnostic value of SARC-F and SARC-CalF scores for sarcopenia was assessed by determining the sensitivity, specificity, PPV, NPV, LR+, LR−, and area under the curve (AUC) (Table 6) as well as the ROC curves for SARC-F and SARC-CalF scores, shown in Fig. 1. The AUCs were 0.70 for SARC-F and 0.88 for SARC-CalF, with SARC-CalF showing a significantly higher AUC than SARC-F ($P < .001$).

### 4. Discussion

Our findings showed that 20.9% of the overall study population with chronic musculoskeletal pain, and 9.3% of the participants aged <65 years, had sarcopenia. The SARC-F and SARC-CalF scores were significantly correlated with not only sarcopenia-related factors but also NRS and PDAS scores in univariate analysis and with the PDAS score, SMI, and gait speed in multivariate analysis. In assessments of the sarcopenia screening capacity in chronic pain patients, both SALC-F and SARC-CalF showed moderate diagnostic power in the ROC curve analysis, with SARC-CalF showing a higher diagnostic power than SARC-F.
Table 6
Correlations of SARC-F and SARC-CalF scores with the other measured parameters.

|                    | Sensitivity, % | Specificity, % | PPV % | NPV, % | +LR     | −LR     | AUC    | P value |
|--------------------|----------------|----------------|-------|--------|---------|---------|--------|---------|
| All ages           |                |                |       |        |         |         |        |         |
| SARC-F             | 55.6 (38.1–72.1) | 71.3 (62.9–78.7) | 33.9 (22.1–47.4) | 85.8 (78.0–91.7) | 1.94 (1.31–2.87) | 0.62 (0.43–0.91) | 0.70 (0.60–0.79) | < .001 |
| SARC-CalF          | 80.6 (64.0–91.8) | 77.9 (70.0–84.6) | 49.2 (35.9–62.5) | 93.8 (87.7–97.5) | 3.65 (2.56–5.21) | 0.25 (0.13–0.49) | 0.88 (0.83–0.93) |
| >65 years          |                |                |       |        |         |         |        |         |
| SARC-F             | 62.1 (42.3–79.3) | 57.4 (44.8–69.3) | 38.3 (24.5–53.6) | 78.0 (64.0–88.5) | 1.46 (0.98–2.16) | 0.67 (0.40–1.10) | 0.66 (0.54–0.77) | < .001 |
| SARC-CalF          | 89.7 (72.6–97.8) | 70.6 (58.3–81.0) | 56.5 (41.1–71.1) | 94.1 (83.8–98.8) | 3.05 (2.07–4.50) | 0.15 (0.05–0.43) | 0.87 (0.81–0.94) |
| ≤65 years          |                |                |       |        |         |         |        |         |
| SARC-F             | 28.6 (3.7–71.0) | 85.3 (74.6–92.7) | 16.7 (2.1–48.4) | 92.1 (82.4–97.4) | 1.94 (0.53–7.16) | 0.84 (0.52–1.35) | 0.62 (0.37–0.86) | .139  |
| SARC-CalF          | 42.9 (9.9–81.6) | 85.3 (74.6–92.7) | 23.1 (5.0–53.8) | 93.5 (84.3–98.2) | 2.91 (1.04–8.16) | 0.67 (0.35–1.28) | 0.82 (0.72–0.92) |

Values within parenthesis show 95 % confidential intervals. P value represents the difference of the AUC between SARC-F and SARC-CalF in each group.

+LR = positive likelihood ratio, −LR = negative likelihood ratio, AUC = area under the curve, NPV, negative predictive value, PPV = positive predictive value.

Figure 1. The receiver operating characteristic (ROC) curves of SARC-F and SARC-CalF for diagnosing sarcopenia against age: (A) all ages, (B) >65 years, and (C) ≤65 years.
In patients with chronic musculoskeletal pain, physical function and activity are impaired from a relatively early age. Sarcopenia may result in similar impairments; in this study, approximately 10% of the patients <65 years of age were diagnosed with sarcopenia, and for the same degree of pain, patients with sarcopenia showed a significantly greater pain-induced reduction in activity. This result may represent a vicious cycle: prolonged pain decreases physical activity, thereby reducing muscle mass, causing greater prolonged pain, and causing further reductions in activity. However, since the time course of pain-induced loss of physical activity and muscle loss could not be evaluated from this study, further studies are warranted on this topic.

For screening sarcopenia in patients with chronic musculoskeletal pain, both SARC-F and SARC-CalF showed moderate diagnostic power. A previous study in community-dwelling older adults revealed that the AUC of SARC-F ranged from 0.79 to 0.89 using various diagnostic criteria. In our study, the AUC of SARC-F was 0.72, which was thought to be similar to the previously reported findings. SARC-CalF was originally developed to enhance the SARC-F sensitivity by incorporating CC as a muscle mass surrogate into the SARC-F; and SARC-CalF has indeed been shown to have significantly better sensitivity (66.7%) in comparison with SARC-F (53.3%) for all studied age groups. Similar results have been reported for community-dwelling older adults, patients with cancer, and patients with chronic pain who have participated in our study. In assessments of their reliability as screening tools, both SARC-F and SARC-CalF scores were correlated with PDAS scores, which indicated pain-related disability. In other words, SARC-F and SARC-CalF are not only screening tools for sarcopenia but also simple tools to assess disability in patients with chronic musculoskeletal pain. This study has several limitations. First, since sarcopenia is a concept primarily applicable in older patients, its use in people <65 years is controversial. However, a previous longitudinal study revealed that leg skeletal muscle mass starts to decrease in the 40s, and chronic musculoskeletal pain can exacerbate muscle mass and physical function reduction. Although the use of the term sarcopenia in younger ages is controversial, clinical attention should be paid to muscle mass and physical function maintenance in patients with chronic musculoskeletal pain, even at a younger age. Second, since this study was conducted in Japanese participants and we used the AWGS criteria for sarcopenia diagnosis, the results may differ in studies involving other populations and using other sarcopenia criteria, such as those proposed by the European Working Group on Sarcopenia in Older People or the International Working Group on Sarcopenia. Third, in this study, patients with chronic pain were evaluated mainly from the viewpoint of physical function and activity, although pain chronicity is related to a complex interplay of psychological and social factors, and such factors were not considered in this study. Fourth, since this was a cross-sectional study, it was difficult to evaluate the chronological order between sarcopenia and chronic pain. Fifth, while musculoskeletal pain includes rest and motion pain, we used average pain intensity in the past 1 week of NRS as a comprehensive and representative concept including exercise and resting pain. Based on these limitations, further prospective studies are needed to explore the relationships of sarcopenia with pain-related factors and outcomes after treatment in patients with chronic musculoskeletal pain.

This study demonstrated that, among patients with chronic musculoskeletal pain, sarcopenia was present in patients <65 years of age. While both SARC-F and SARC-CalF were shown to be reliable screening methods, SARC-CalF was the more reliable tool for detecting sarcopenia. Further studies are needed to assess the chronological relationship between sarcopenia and chronic musculoskeletal pain.

Acknowledgments

The authors would like to thank all the medical staff who collaborated on this study.

Author contributions

Conceptualization: HT and Tomoko T. Methodology: HT and Tomonori T. Formal analysis and investigation: HT and Tomonori T. Writing – original draft preparation: HT, Tomoko T and Tomonori T. Writing – review and editing: YO and HM.

Funding acquisition: TT. Resources: TT and ST. Supervision: KN and TO.

References

[1] Nakamura K. The concept and treatment of locomotive syndrome: its acceptance and spread in Japan. J Orthop Sci. 2011;16:489–91.
[2] Dos Santos L, Cyrino ES, Antunes M, et al. Sarcopenia and physical independence in older adults; the independent and synergic role of muscle mass and muscle function. J Cachexia Sarcopenia Muscle. 2017;8:245–50.
[3] Akune T, Muraki S, Oka H, et al. Incidence of certified need of care in the long-term care insurance system and its risk factors in the elderly of Japanese population-based cohorts: the ROAD study. Geriatr Gerontol Int. 2014;14:695–701.
[4] Morley JE, Abbatecola AM, Argiles JM, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. 2011;12:403–9.
[5] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
[6] Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21:300–307.e2.
[7] Rolland Y, Czerwinski S, Abellán Van Kan G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12:433–50.
[8] Morley JE, Baumgartner RN, Roubenoff R, et al. Sarcopenia. J Lab Clin Med. 2001;137:231–43.
[9] Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(suppl 5):990s–1s.
[10] Evans WJ, Campbell WW. Sarcopenia and age-related changes in body composition and functional capacity. J Nutr. 1993;123(suppl 2):465–8.
[11] Zhang Y, Hao Q, Ge M, et al. Association of sarcopenia and fractures in community-dwelling older adults: a systematic review and meta-analysis of cohort studies. Osteoporos Int. 2018;29:1253–62.
[12] Wong RMY, Wong H, Zhang N, et al. The relationship between sarcopenia and fragility fracture—a systematic review. Osteoporos Int. 2019;30:541–53.
[13] Yeung SSY, Reijnierse EM, Pham VK, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10:485–500.
[14] Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14:531–2.
[15] Barbosa-Silva TG, Menezes AM, Bielemann RM, et al. Enhancing SARC-F: improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc. 2016;17:3136–41.
[16] Blay ME, March LM, Brnic A, et al. Chronic pain in Australia: a prevalence study. Pain. 2001;89:127–34.
[17] Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
[18] Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). Pain. 2019;160:19–27.
[19] Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003–7.
[20] Tsuji H, Tetsunaga T, Tetsunaga T, et al. Cognitive factors associated with locomotive syndrome in chronic pain patients: A retrospective study. J Orthop Sci. 2021;26:896–901.
[21] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in older people. Age Ageing. 2010;39:412–23.
[22] Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence,
etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249–56.

[23] Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36.

[24] Ida S, Murata K, Nakadachi D, et al. Development of a Japanese version of the SARC-F for diabetic patients: an examination of reliability and validity. Aging Clin Exp Res. 2017;29:935–42.

[25] Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117–26.

[26] Yamashiro K, Arimura T, Iwaki R, et al. A multidimensional measure of pain interference: reliability and validity of the pain disability assessment scale. Clin J Pain. 2011;27:338–43.

[27] Faul F, Erdfelder E, Lang AG, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.

[28] Yang M, Hu X, Xie L, et al. Screening sarcopenia in community-dwelling older adults: SARC-F vs SARC-F combined with calf circumference (SARC-CalF). J Am Med Dir Assoc. 2018;19:e1–e8.

[29] Fu X, Tian Z, Thapa S, et al. Comparing SARC-F with SARC-CalF for screening sarcopenia in advanced cancer patients. Clin Nutr. 2020;39:3337–45.

[30] Kitamura I, Koda M, Otsuka R, et al. Six-year longitudinal changes in body composition of middle-aged and elderly Japanese: age and sex differences in appendicular skeletal muscle mass. Geriatr Gerontol Int. 2014;14:354–61.